Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III).

Women with both a history of high grade cervical intraepithelial neoplasia (CIN III) and breast carcinoma as second primary cancer were selected for studying the presence of HPV in breast carcinomas. Paraffin embedded material from 38 patients with 41 breast carcinoma cases after CIN III were examined by polymerase chain reaction (PCR) and in situ hybridization. By PCR we detected HPV 16 DNA in 19 out of 41 cases (46%) of the breast carcinomas. One case proved to be HPV 16 positive also by in situ hybridization. HPV 16 was also detected in 32 out of the 38 patients with CIN III (84%). All HPV 16 positive breast carcinomas were HPV 16 positive in their corresponding CIN III lesions. Eight patients with diagnosed breast cancer before the CIN III lesions were used as controls. None of these had HPV positive breast carcinomas. No cases were positive for HPV 11, 18, or 33. HPV 16 was detected in the primary tumours, in local metastases from HPV 16 positive tumours, in a distant HPV 16 positive breast carcinoma metastasis to the colon, and in other primary cancers in patients with HPV 16 positive breast carcinomas and HPV 16 positive CIN III. Estrogen and progesterone receptors were quantified in the HPV positive and HPV negative breast carcinomas, and there was no significant difference in the fraction positive in the two groups. Oncogenic HPV DNA might be transported from an original site of infection to other organs by blood or lymph, and possibly be a factor in the development of cancer in different organs.

[1]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[2]  F. Perera,et al.  Carcinogen-DNA adducts in human breast tissue. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  G. Higgins,et al.  Alzheimer's retraction , 1992, Nature.

[4]  M. Schoenberg,et al.  Human papillomavirus associated with bladder cancer. , 1992, Urology.

[5]  T. Bjørge,et al.  Second primary cancers in patients with carcinoma in situ of the uterine cervix. The norwegian experience 1970–1992 , 1995, International journal of cancer.

[6]  N. Shepherd,et al.  Clinical and pathological correlates of HPV type 16 DNA in anal cancer , 1990, International Journal of Colorectal Disease.

[7]  S. Syrjänen,et al.  Human papillomavirus involvement in esophageal precancerous lesions and squamous cell carcinomas as evidenced by microscopy and different DNA techniques. , 1992, Scandinavian journal of gastroenterology.

[8]  S. Watts,et al.  Human papillomavirus DNA types in squamous cell carcinomas of the head and neck. , 1991, Oral surgery, oral medicine, and oral pathology.

[9]  P. Devilee,et al.  Genes responsible for familial breast cancer. , 1996, Pathology, research and practice.

[10]  X. Sastre,et al.  Estrogen and progesterone receptors in cervical human papillomavirus related lesions , 1991, International journal of cancer.

[11]  R. Schlegel,et al.  Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. , 1985, The American journal of pathology.

[12]  E. Pettersen,et al.  Use of multiple PCR primer sets for optimal detection of human papillomavirus , 1996, Journal of clinical microbiology.

[13]  R. Coombes,et al.  Absence of HPV 16 and 18 DNA in breast cancer. , 1992, British Journal of Cancer.

[14]  S. Yousem,et al.  Occurrence of Human Papillomavirus DNA in Primary Lung Neoplasms , 1992, Cancer.

[15]  J. Bornstein,et al.  Human papillomavirus associated with adenocarcinoma and adenosquamous carcinoma of the cervix: analysis by in situ hybridization , 1989, Gynecologic oncology.

[16]  W H Woolley,et al.  Theoretical biology and biophysics , 1971 .

[17]  H. Bernard,et al.  Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia , 1989, Journal of virology.

[18]  E. Thorsby,et al.  HLA antigens and cervical carcinoma , 1992, Nature.

[19]  H. Hausen INTRACELLULAR SURVEILLANCE OF PERSISTING VIRAL INFECTIONS Human Genital Cancer Results from Deficient Cellular Control of Papillomavirus Gene Expression , 1986, The Lancet.

[20]  P. Stern,et al.  HLA antigens and cervical carcinoma , 1992, Nature.

[21]  A. López-Beltran,et al.  Human papillomavirus infection and transitional cell carcinoma of the bladder. Immunohistochemistry and in situ hybridization. , 1996, Pathology, research and practice.

[22]  C. Meijer,et al.  The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. , 1995, The Journal of general virology.

[23]  V. Diehl,et al.  Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma , 1982, Journal of virology.

[24]  H. Hausen,et al.  A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. , 1984, The EMBO journal.

[25]  J. Nesland,et al.  In situ hybridization with nonisotopic probes using different detection systems. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[26]  S. Jabłońska,et al.  Human papillomavirus-associated tumors of the skin and mucosa. , 1997, Journal of the American Academy of Dermatology.

[27]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[28]  R. Biggar,et al.  Second primary cancers following anal and cervical carcinoma: evidence of shared etiologic factors. , 1992, American journal of epidemiology.

[29]  K. Mullis,et al.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. , 1988, Science.

[30]  G. Bratthauer,et al.  Etiology of breast carcinoma: no apparent role for papillomavirus types 6/11/16/18. , 1992, Pathology, research and practice.

[31]  D. Shibata,et al.  Detection of human papilloma virus in paraffin-embedded tissue using the polymerase chain reaction , 1988, The Journal of experimental medicine.

[32]  S. Watanabe,et al.  Human papillomavirus DNA in squamous cell carcinomas of the respiratory and upper digestive tracts. , 1993, Japanese journal of clinical oncology.

[33]  Anna Di Lonardo,et al.  Human papillomavirus in breast cancer , 2005, Breast Cancer Research and Treatment.

[34]  J. Bornstein,et al.  Human papillomavirus associated with adenocarcinoma and adenosquamous carcinoma of the cervix: analysis by in situ hybridization , 1990, Gynecologic oncology.

[35]  Thomas F. Smith,et al.  Polymerase chain reaction (PCR) identification of human papillomavirus (HPV) DNA in verrucous carcinoma of the larynx , 1993, The Laryngoscope.

[36]  L. Gissmann,et al.  A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Waterhouse Cancer incidence in five continents, v.3 , 1976 .

[38]  C. la Vecchia,et al.  Incidence of invasive cancers following carcinoma in situ of the cervix. , 1996, British Journal of Cancer.

[39]  D. Phillips,et al.  DNA adduct assay in cervical epithelium , 1994, Diagnostic cytopathology.

[40]  A. Wyllie,et al.  HPV in full thickness cervical biopsies: High prevalence in CIN 2 and CIN 3 detected by a sensitive PCR method , 1991, The Journal of pathology.

[41]  C. Lai,et al.  Identification of human papillomavirus DNA sequences in peripheral blood mononuclear cells. , 1991, American journal of clinical pathology.

[42]  D. Spandidos,et al.  Detection of human papilloma virus (HPV) and K-ras mutations in human lung carcinomas. , 1996, International journal of oncology.

[43]  C. McNeil HPV vaccines for cervical cancer move toward clinic, encounter social issues. , 1997, Journal of the National Cancer Institute.

[44]  L. Huang,et al.  Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. , 1996, Biochemical and biophysical research communications.

[45]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[46]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[47]  A. Vecchione,et al.  High frequency of human papillomavirus detection in urinary bladder cancer. , 1994, Urologia internationalis.

[48]  C. Mies,et al.  Extraction of DNA from paraffin blocks for Southern blot analysis. , 1991, The American journal of surgical pathology.

[49]  I. Schedel,et al.  Cellular immunodeficiency enhances the progression of human papillomavirus‐associated cervical lesions , 1994, International journal of cancer.

[50]  C. Dickson 3. Role of the INT‐genes in murine mammary tumor development and implications for human breast cancer , 1990 .

[51]  D. Medina Preneoplastic lesions in murine mammary cancer. , 1976, Cancer research.

[52]  T. Dragani,et al.  Libri Ricevuti: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans , 1992 .

[53]  A. Rustgi,et al.  Human papillomavirus DNA sequences in esophagus squamous cell carcinoma. , 1994, Gastroenterology.

[54]  M. M. Pater,et al.  Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives. , 1990, American journal of obstetrics and gynecology.

[55]  H. Popper,et al.  Prognostic importance of human papilloma virus typing in squamous cell papilloma of the bronchus: comparison of in situ hybridization and the polymerase chain reaction. , 1994, Human pathology.

[56]  D. Easton,et al.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. , 1993, American journal of human genetics.

[57]  M. Campion,et al.  Subpopulations of Langerhans’ cells in cervical neoplasia , 1987 .

[58]  D. Jenkins,et al.  Lymphocyte phenotypes in cervical intraepithelial neoplasia and human papillomavirus infection , 1987 .

[59]  M. M. Pater,et al.  Multiple human papillomavirus type 16 glucocorticoid response elements functional for transformation, transient expression, and DNA-protein interactions , 1993, Journal of virology.

[60]  V. Band,et al.  Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[61]  B. Das,et al.  Absence of human papillomavirus DNA in breast cancer as revealed by polymerase chain reaction , 2005, Breast Cancer Research and Treatment.

[62]  L. Brinton,et al.  Second primary cancers after vulvar and vaginal cancers. , 1996, American journal of obstetrics and gynecology.

[63]  N. Shepherd,et al.  Human papillomavirus type 16 DNA in anal cancers from six different countries. , 1991, Gut.

[64]  M. M. Pater,et al.  Role of steroid hormones in potentiating transformation of cervical cells by human papillomaviruses. , 1994, Trends in microbiology.

[65]  K. Mullis,et al.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. , 1985, Science.

[66]  Y. Chardonnet,et al.  Human papillomavirus type 11DNA in papillary squamous cell lung carcinoma , 2005, Virchows Archiv A.

[67]  S. Jabłońska,et al.  Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. , 1995, Archives of dermatology.

[68]  Harald zur Hausen,et al.  Papillomavirus infections — a major cause of human cancers , 1996 .

[69]  Henry A. Erlich,et al.  Enzymatic amplification of ?-globin genomic sequences and restriction site analysis for diagnosis of , 1985 .